Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine monotherapy in rituximab-refractory indolent B‑cell lymphoma
CTR20132295Phase 3Completed
- Sponsor
- Shandong Lanjin Bioengineering
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bendamustine in low-grade B-cell lymphoma, sponsored by Shandong Lanjin Bioengineering. Started Feb 2014; status: completed.
02
Drugs
bendamustine
03
Conditions
low-grade B-cell lymphoma
Beyond the preview
Go deeper on CTR20132295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132295.